Effects of Iron Supplementation on Erythropoietic Response in Patients with Cancer-associated Anemia Treated by Means of Erythropoietic Stimulating Agents

Overview

Journal ISRN Hematol

Specialty Hematology

Date 2011 Nov 24

PMID 22111015

Citations 3

Authors

Torbjorn Karlsson

Affiliations

Soon will be listed here.

Abstract

During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The pathogenetic mechanisms behind functional iron deficiency, a major reason for ESA hyporesponsiveness in cancer, will also be described.

Citing Articles

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.

Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M Support Care Cancer. 2017; 25(9):2779-2786.

PMID: 28391437 PMC: 5527057. DOI: 10.1007/s00520-017-3690-z.

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study.

Mouysset J, Freier B, van den Bosch J, Briac Levache C, Bols A, Tessen H Cancer Manag Res. 2016; 8:1-10.

PMID: 26855598 PMC: 4725626. DOI: 10.2147/CMAR.S88110.

Combination treatment with an erythropoiesis-stimulating agent and intravenous iron alleviates anaemia in patients with hereditary haemorrhagic telangiectasia.

Cherif H, Karlsson T Ups J Med Sci. 2014; 119(4):350-3.

PMID: 25188751 PMC: 4248076. DOI: 10.3109/03009734.2014.955619.

References

Ludwig H, Fritz E, KOTZMANN H, Hocker P, Gisslinger H, Barnas U . Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990; 322(24):1693-9. DOI: 10.1056/NEJM199006143222402. View

Rizzo J, Brouwers M, Hurley P, Seidenfeld J, Arcasoy M, Spivak J . American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116(20):4045-59. DOI: 10.1182/blood-2010-08-300541. View

Fishbane S, Frei G, Maesaka J . Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995; 26(1):41-6. DOI: 10.1016/0272-6386(95)90151-5. View

Agarwal R, Vasavada N, Sachs N, Chase S . Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004; 65(6):2279-89. DOI: 10.1111/j.1523-1755.2004.00648.x. View

Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto T . Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008; 26(10):1611-8. DOI: 10.1200/JCO.2006.10.4620. View

Auerbach M, Silberstein P, Webb R, Averyanova S, Ciuleanu T, Shao J . Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol. 2010; 85(9):655-63. DOI: 10.1002/ajh.21779. View

Nowrousian M . Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol. 1998; 15 Suppl 1:S19-28. View

Pedrazzoli P, Farris A, Prete S, Del Gaizo F, Ferrari D, Bianchessi C . Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008; 26(10):1619-25. DOI: 10.1200/JCO.2007.12.2051. View

Salahudeen A, Oliver B, Bower J, Roberts 2nd L . Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 2001; 60(4):1525-31. DOI: 10.1046/j.1523-1755.2001.00976.x. View

10.

Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, ESSERS U . Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood. 1995; 86(12):4446-53. View

11.

Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen O, Ganz T . Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2004; 105(4):1797-802. DOI: 10.1182/blood-2004-08-3375. View

12.

Bailie G, Clark J, Lane C, Lane P . Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005; 20(7):1443-9. DOI: 10.1093/ndt/gfh820. View

13.

Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, Antoni G . Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003; 120(5):853-9. DOI: 10.1046/j.1365-2141.2003.03590.x. View

14.

Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt K . Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 Suppl 2:ii1-47. DOI: 10.1093/ndt/gfh1032. View

15.

Viatte L, Nicolas G, Lou D, Bennoun M, Lesbordes-Brion J, Canonne-Hergaux F . Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood. 2005; 107(7):2952-8. DOI: 10.1182/blood-2005-10-4071. View

16.

Agarwal R . Nonhematological benefits of iron. Am J Nephrol. 2007; 27(6):565-71. DOI: 10.1159/000107927. View

17.

Fishbane S, Ungureanu V, Maesaka J, Kaupke C, Lim V, Wish J . The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996; 28(4):529-34. DOI: 10.1016/s0272-6386(96)90463-1. View

18.

Hoen B, Hestin D, Kessler M . EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998; 9(5):869-76. DOI: 10.1681/ASN.V95869. View

19.

Henry D, Dahl N, Auerbach M, Tchekmedyian S, Laufman L . Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12(2):231-42. DOI: 10.1634/theoncologist.12-2-231. View

20.

Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B . Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007; 21(4):627-32. DOI: 10.1038/sj.leu.2404562. View